The Metabolic State of E. coli Influences Fosfomycin Efficacy and Promotes Resistance Evolution
ACS Infectious Diseases · 13.03.2026 · 12 (3) · 1155-1164
DOI: 10.1021/acsinfecdis.5c01013 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 10.02.2026. Verfasst von Andreas Verhülsdonk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, 72076 Tübingen, Germany. Hauptthemen laut MEDLINE: Fosfomycin, Escherichia coli, Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
The phosphonic antibiotic fosfomycin is a bacterial cell wall synthesis inhibitor that targets MurA, the first enzyme in the peptidoglycan pathway. Transporter loss or enzymatic inactivation confers resistance to fosfomycin, but whether the metabolic state of a bacterium influences the efficacy of this antibiotic has not been characterized. Here, we used an Escherichia coli CRISPR interference library targeting 1,515 metabolic genes to identify metabolic activities that influence fosfomycin efficacy. We discovered that knockdowns of ATP synthase and pyruvate kinase genes lead to a regrowth phenotype, whereby cells resume growth after an initial phase of killing. By following up on this phenotype with population analysis profile tests and repeated treatment cycles, we found evidence that a heteroresistant population may promote the evolution of fosfomycin resistance. Whole-genome sequencing of the pykF CRISPRi strain after 24 h of fosfomycin exposure revealed that the acid stress protein-encoding gene ibaG, which is upstream of murA, carries a mutation that confers fosfomycin resistance. Metabolome analysis showed accumulation of the MurA substrate phosphoenolpyruvate in regrowing cells, which may compete with fosfomycin for binding to MurA. Transcriptome analysis provided further insight into the mechanism of cell regrowth, including upregulation of genes encoding cell envelope stress response regulators such as cpxP. These results suggest that the metabolic state can modulate the efficacy of fosfomycin and contribute to resistance evolution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interfaculty Institute of Microbiology and Infection Medicine, University of Tübingen, 72076 Tübingen, Germany.
- Cluster of Excellence "Controlling Microbes to Fight Infections", University of Tübingen, 72076 Tübingen, Germany.
- M3 Research Center, University of Tübingen, Otfried-Müller-Str. 37, 72076 Tübingen, Germany.
- Quantitative Biology Center (QBiC), University of Tübingen, Otfried-Müller-Str. 37, 72076 Tübingen, Germany.
ORCID-Profile: Fabian Smollich, Hannes Link
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Verhülsdonk, A., Stadelmann, A., Smollich, F., Rapp, J., Straub, D., & Link, H. (2026). The Metabolic State of E. coli Influences Fosfomycin Efficacy and Promotes Resistance Evolution. ACS Infectious Diseases, 12(3), 1155-1164. https://doi.org/10.1021/acsinfecdis.5c01013
Vancouver
Verhülsdonk A, Stadelmann A, Smollich F, Rapp J, Straub D, Link H. The Metabolic State of E. coli Influences Fosfomycin Efficacy and Promotes Resistance Evolution. ACS Infectious Diseases. 2026;12(3):1155-1164. doi:10.1021/acsinfecdis.5c01013
BibTeX
@article{Verhlsdonk2026,
author = {Verhülsdonk, Andreas and Stadelmann, Amelie and Smollich, Fabian and Rapp, Johanna and Straub, Daniel and Link, Hannes},
title = {The Metabolic State of E. coli Influences Fosfomycin Efficacy and Promotes Resistance Evolution},
journal = {ACS Infectious Diseases},
year = {2026},
volume = {12},
number = {3},
pages = {1155--1164},
doi = {10.1021/acsinfecdis.5c01013}
}
EUVIMED